| 注册
首页|期刊导航|北京中医药|糖复康方对自发性糖尿病小鼠的治疗作用及机制

糖复康方对自发性糖尿病小鼠的治疗作用及机制

闫凯 王燕 王威 李建辉 冯兴中

北京中医药2025,Vol.44Issue(2):142-148,7.
北京中医药2025,Vol.44Issue(2):142-148,7.DOI:10.16025/j.1674-1307.2025.02.006

糖复康方对自发性糖尿病小鼠的治疗作用及机制

Therapeutic effect and mechanism of Tangfukang Formula on KKAy diabetes mice

闫凯 1王燕 2王威 3李建辉 1冯兴中3

作者信息

  • 1. 首都医科大学附属北京朝阳医院中医科,北京 100043
  • 2. 民航总医院中医科,北京 100123
  • 3. 清华大学玉泉医院(清华大学中西医结合医院)内分泌科,北京 100040
  • 折叠

摘要

Abstract

Objective To observe the therapeutic effect and mechanism of the Tangfukang Formula on spontaneous diabetes(KKAy)mice.Methods Thirty-six KKAy mice and six C57BL/6J wild-type mice were selected,with C57BL/6J mice serving as the normal group and receiving a normal diet,while KKAy mice were given a high-fat diet.The 36 KKAy mice were randomly divided into model group,Chinese medicine group,Chinese medicine+inhibitor group,and agonist group according to a random number table,with 9 mice in each group.The Chinese medicine group and Chinese medicine+inhibitor group were administered 3.2 g/(kg·d)of Tangfukang Formula by gavage.The normal,model,and agonist groups received an equivalent volume of physiological saline by gavage,once per day for 4 weeks.The agonist group was injected intraperitoneally with 0.5 g/(kg·d)5-aminoimidazole-4-carboxamide ribonucleotide(AICAR),and the Chinese medicine+inhibitor group was injected with 5 mg/(kg·d)compound C(CC)intraperitoneally.The normal,model,and Chinese medicine groups received an equivalent volume of phosphate buffer solution by intraperitoneal injection,once per day for 4 weeks.Random blood glucose(RBG),oral glucose tolerance test(OGTT),plasma adiponectin(APN)and branched-chain amino acids(BCAA),protein expression levels of AMPKα,p-AMPKα,BCKDH-E1α,and p-BCKDH-E1α in skeletal muscle,as well as histopathological changes in skeletal muscle and pancreatic tissues,were assessed.Safety indicators were also measured.Result After 2 weeks of intervention,RBG levels in the Chinese medicine group and agonist group were lower than those in the Chinese medicine+inhibitor group(P<0.01),with no significant difference between the Chinese medicine and agonist groups(P>0.05).After 4 weeks,RBG levels in the Chinese medicine and agonist groups were significantly reduced compared to those before treatment(P<0.01),and their RBG levels were lower than those of the model group at all observed time points(P<0.01).After 4 weeks,plasma APN levels in the model group were lower than in the normal group,while BCAA levels were higher(P<0.05).Compared with the model group,both the Chinese medicine and agonist groups had higher APN levels and lower BCAA levels(P<0.01).There was no significant difference in APN and BCAA levels between the Chinese medicine+inhibitor group and the model group(P>0.05).Histopathological examination showed that in the Chinese medicine and agonist groups,skeletal muscle cells were more orderly with less edema,atrophy,and rupture of muscle fibers,and fewer inflammatory cells.In these groups,the levels of p-AMPKα/AMPKα and p-BCKDH-E1α/BCKDH-E1α in skeletal muscle tissue were significantly higher(P<0.05).Compared with the model group,the Chinese medicine and agonist groups showed significantly lower alanine aminotransferase(ALT)levels(P<0.01),while there was no significant difference in the Chinese medicine+inhibitor group(P>0.05).The Chinese medicine group also showed significantly lower aspartate aminotransferase(AST),urea,and creatinine(Crea)levels compared to the model group(P<0.05),while no significant differences were observed in the agonist and Chinese medicine+inhibitor groups(P>0.05).Conclusion Tangfukang Formula has a clear effect on improving the metabolism of glucose and lipid in KKAy diabetes mice,and has good safety.Its mechanism may be related to APN-AMPK-BCAA signaling pathway.

关键词

糖复康方/糖尿病/脂联素/腺苷5-单磷酸激活蛋白激酶/支链氨基酸/信号通路/自发性糖尿病小鼠

Key words

Tangfukang Formula/diabetes mellitus/APN/AMPK/BCAA/signaling pathway/KKAy mice

引用本文复制引用

闫凯,王燕,王威,李建辉,冯兴中..糖复康方对自发性糖尿病小鼠的治疗作用及机制[J].北京中医药,2025,44(2):142-148,7.

基金项目

首都卫生发展科研专项(首发2022-2-4131) (首发2022-2-4131)

北京市中医药科技发展资金项目(BJZYZD-2023-01) (BJZYZD-2023-01)

北京中医药

1674-1307

访问量0
|
下载量0
段落导航相关论文